Margaretta Colangelo on Longevity2020

Latest articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

X marks the spot for meaningful information on aging and cognition

Understanding chromosomal differences between men and women could be the X Factor when it comes to tackling cognitive decline. A new paper published in Jama...

Most read

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Editor's picks

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

Click the globe for translations.

An in-depth preview of big-hitting AI speakers at the first ever online Longevity conference.

It’s finally here – Longevity2020 week has arrived! Later today, we get things going with our first session Defining biological aging, followed by a different theme every day this week. To kick things off, we wanted to share a guest post from the wonderful Margaretta Colangelo, co-founder and managing partner at Deep Knowledge Ventures. A huge thank you to Margaretta, who was instrumental in helping us put together the conference programme, and we look forward to her Wednesday session on AI & Longevity.

Note that Margaretta’s post first appeared on LinkedIn: https://www.linkedin.com/pulse/next-week-longevity2020-first-global-online-longevity-colangelo/

This week, Longevity experts from around the world will come together for Longevity2020 the first worldwide online Longevity conference. Scientists, investors, and CEOs will share the latest research, innovations, and opinions. The conference will run over 5 days and include presentations, fireside chats, and Q&A sessions. At the end of each session there will be ‘ask me anything’ sessions with speakers which provides a unique opportunity to network with the key players in the Longevity sector. To register for Longevity2020 please go to the Longevity Technology website.

Longevity2020

On Wednesday we will kick off the AI for Longevity Program with a conversation with three scientists who are applying AI and big data analytics for healthy longevity. We will speak with John Shepherd, PhD, Richard Siow, PhD, and Alex Zhavoronkov, PhD. John Shepherd PhD is co-founder of the AI Precision Health Institute (AI-PHI) at the University of Hawai‘i Cancer Center. Dr. Shepherd and his team are using AI and machine learning to quantify human health and predict risk of disease. Dr. Shepherd will discuss how he and his team use AI to analyze body composition to predict risk of disease, fractures, and frailty. The AI-PHI is conducting population based and laboratory based research to determine how ethnic, cultural, and environmental factors impact human health. Since Hawaii has one of the most diverse populations in the world, it’s an ideal place to study how genetic susceptibility interacts with environmental factors to impact health. Research conducted at the AI-PHI is unique and can only been done in Hawaii because Hawaii has the longest life expectancy and the most ethnic diversity of any state in the US. (Image of the interior of the AI-PHI).

We will discuss how AI is used in medical imaging and stem cell biology with Richard Siow PhD, Director of the Longevity AI Consortium (LAIC), at Kings College London. AI for Longevity is an underrepresented sector in the Longevity Industry despite having more potential to increase Healthy Longevity in the short term than any other sector. The LAIC will work to facilitate the shift from treatment to prevention and from preventive medicine to real-world precision health. The initial aim will be to identify novel longevity and healthy ageing biomarkers to accelerate diagnosis of age-related health decline. Then researchers will develop personalized physical, mental and financial health to better implement and promote healthy lifestyles for longevity, such as modifying patterns in sleep, nutrition, physical activity, environmental exposure, and financial planning. The Consortium will use King’s world-leading advances in genetics, AI, and aging research to develop advanced personalized diagnostics, prognostics, and therapeutic benchmarking developed by Aging Analytics Agency. King’s College London was the logical choice of location for the first Longevity AI Consortium, due to their unique combination of resources, departments, and technologies for both AI and Longevity. The Consortium launched with strategic and financial support from Deep Knowledge Ventures and The Biogerontology Research Foundation.

AI speakers on Longevity

The Longevity AI Consortium is based at King’s College London.

We will also speak with Alex Zhavoronkov, PhD, CEO of Insilico Medicine and chief scientist of the Biogerontology Research Foundation. Insilico Medicine is applying the latest advances in AI to drug discovery, biomarker development, and aging research. The Biogerontology Research Foundation is the UK’s leading non-profit focused on Longevity and Aging research. The Foundation has supported multiple initiatives relating to advancing Healthy Longevity. It provided financial and organizational support to Longevity International UK for the purpose of establishing the UK All-Party Parliamentary Group for Longevity, and to Ageing Research at King’s for the purpose of establishing the Longevity AI Consortium at King’s College London. The Foundation was also actively involved in the successful initiative to add a new extension code for “ageing-related diseases” accepted in 2018 by the World Health Organization during the last revisions of its International Classification of Diseases framework.

Ovarian Longevity webinar

On Thursday, Dmitry Kaminskiy will speak in the Longevity Investing Program about global pandemics and accelerated investment in Longevity. Dmitry Kaminskiy is an investor active in the fields of Longevity, Precision Medicine, and AI. He is co-founder and managing partner at Deep Knowledge Ventures, a leading investment fund focused on DeepTech, known for its use of sophisticated analytical systems for investment target identification and due-diligence. He was instrumental at the initial stage of the launch of the All-Party Parliamentary Group for Longevity in the UK Parliament and now serves as co-director of the secretariat, overseeing the APPG’s international Longevity cooperation development division. He is also supervising all of the APPG’s activities related to the development of Centers of AI for Preventive Medicine in the UK. Dmitry adheres to the principal of Impact Investing, believing that business should intentionally make a significant impact for social good. He operates according to the maxim that business should be aligned with societal good and humanitarianism, and his activities in both business and the non-profit sector are aimed at the shared goal of advancing exponential and disruptive technologies to accelerate positive paradigm shifts in finance, healthcare, and AI.

AI speakers at AAA

Program Overview

Monday – Defining Biological Aging

No alt text provided for this image

On Monday, the Defining Biological Aging Program will address the need for candidate definitions from different biological, clinical, logical and computational angles to adopt a consensus definition for biological aging, and more.

No alt text provided for this image

Tuesday- Rejuvenation Therapies

No alt text provided for this image

On Tuesday, the Rejuvenation Therapies Program will explore senolytics, gene editing, peptides, stem cells, immunotherapy, mitochondrial restoration, and neutraceuticals, and more.

No alt text provided for this image

Wednesday – AI and Longevity

AI speakers

On Wednesday in the AI and Longevity Program AI experts will discuss AI in medical imaging, AI in stem cells, AI in precision health, molecule identification, pre-clinical validation, digital health, lifestyle interventions, and more.

AI speakers at Longevity2020

Thursday – Longevity Investing

No alt text provided for this image

On Thursday, in the Longevity Investing Program, Longevity investors will discuss investment platforms, risk management, and emerging technologies including 3D bio-printing, neuroceuticals, organ growth, Agetech, and more.

No alt text provided for this image

Friday – Longevity Experts

No alt text provided for this image

On Friday, Longevity experts will discuss what you can do now for healthy Longevity including supplements, metformin, mTOR, NAD+, rapamycin, biohacking, fasting, biomarker tracking, monitoring apps, and more.

AI speakers and Longevity start now

REGISTER

Ovarian Longevity webinar

Please register for Longevity2020 on the Longevity Technology website

SPEAKERS

No alt text provided for this image
No alt text provided for this image
No alt text provided for this image
No alt text provided for this image

REGISTER

Please register for Longevity2020 on the Longevity Technology website

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

Related articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

SENS spin-out Underdog closes $10m financing round

Underdog Pharmaceuticals, a key investment of rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Michael Greve’s Kizoo Technology Capital Group led the...

Unlocking ovarian aging could prolong fertility and delay menopause

Ovarian aging is poorly understood, under-researched and under-invested. We need a radical rethink of how we address fertility and the menopause – it's time...

Occuity raises over £2.5m for optical diabetes devices

UK MedTech firm Occuity successfully raises over £2.5m to deliver ophthalmic and optical diabetes devices and is now overfunding on Seedrs to accelerate development. DISCLOSURE:...

Fauna closes $9 million to expand drug discovery platform

Leveraging animal genomics to improve human health, Fauna Bio set to expand its comparative genomics platform for novel target drug discovery. Silicon Valley biotech startup...
Nutriop